Physician profile
Luis E Vasquez
NPI 1366417388
$3,084.15
in general payments reported to CMS, 2019-2025
27 companies · $544 in 2025
The $544 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $143 · 2021: $338 · 2022: $338 · 2023: $447 · 2024: $631 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,621.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $737.76 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $381.50 | 2019-2025 | Otezla, Enbrel, Tavneos |
| Novartis Pharmaceuticals Corporation | $237.63 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $193.66 | 2021-2025 | Saphnelo |
| Horizon Therapeutics Plc | $163.45 | 2019-2023 | Krystexxa |
| Janssen Biotech, INC. | $156.77 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Pfizer INC. | $149.32 | 2019-2022 | |
| Glaxosmithkline, LLC. | $133.10 | 2019-2023 | Benlysta |
| Lilly USA, LLC | $130.28 | 2019-2024 | Taltz, Zepbound |
| Bioventus LLC | $99.99 | 2020-2025 | Xcell, Durolane |
| Fresenius Kabi USA, LLC | $98.66 | 2024-2025 | Idacio |
| Genentech USA, INC. | $88.26 | 2019-2025 | Gazyva, Rituxan, Actemra |
| E.R. Squibb & Sons, L.L.C. | $84.58 | 2019-2021 | |
| Genzyme Corporation | $70.12 | 2019-2025 | |
| Ucb, INC. | $59.71 | 2022-2025 | Bimzelx, Cimzia |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $59.32 | 2023 | Acthar |
| Depuy Synthes Sales INC. | $43.66 | 2021-2025 | Monovisc, Orthovisc |
| Celgene Corporation | $30.98 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $22.99 | 2025 | |
| Sobi, INC | $21.72 | 2024 | |
| Kyowa Kirin, INC. | $19.08 | 2024 | Crysvita |
| Sandoz INC. | $18.76 | 2023 | Hyrimoz |
| Merck Sharp & Dohme LLC | $17.78 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $17.47 | 2023 | Zilretta, Iovera |
| Ani Pharmaceuticals, INC. | $17.24 | 2023 | Purified Cortrophin Gel |
| Pacira Therapeutics, INC. | $17.01 | 2019 | |
| Organon LLC | $13.35 | 2025 | Hadlima, Renflexis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Vasquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.